Podcast Index
Explora podcasts por categoría, abre episodios recientes y descarga audio para escucharlo sin conexión.
Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist
HISTORY This Week
The HISTORY® Channel | Back Pocket Studios
Two Blokes Talking Tech
Trevor Long and Stephen Fenech
Talkin' Sport
Super Radio Network
Hawaii News Now
Hawaii News Now
RFM - PorchatGPT
RFM
ヤマヒロのぴかッとモーニング
MBSラジオ
Holger ruft an
Übermedien
蘭萱時間
蘭萱｜中廣流行網
Learn Spanish with Today's News | A1 Easy Slow Spanish for Beginners
LinguaWire
Macro Hive Conversations With Bilal Hafeez
Bilal Hafeez
时事天下: 实时新闻快讯与深度解读
小明 | 时事天下 (实时新闻)
Gossip News
Gossip News
Pascal Praud et vous
Europe 1
Locked On Mets - Daily Podcast On The New York Mets
Locked On Podcast Network, Ryan Finkelstein
Chinese News
ASTRO Radio News
Camp Kaiju: Monster Movie Podcast
Mischief Tales
Jason On Firms Podcast
Jason Staats
DER WILDE STOIKER – Stoizismus, Gelassenheit und Selbstkontrolle
Guido Bellberg
Le Meilleur des Réveils - l'intégrale
RFM
SRBMedia Sports Podcasts
SRBMedia Sports Podcasts
JUDGE JULES PRESENTS THE GLOBAL WARM UP
Judge Jules
Don Cheto Al Aire
Don Cheto
朗読『声の本棚』
三浦貴子
维明说投资
刘维明
AppleInsider Podcast
AppleInsider
Untold Radio Network
Untold Radio Network
Wall Street Now
ABC News
Journal Afrique
RFI
Up All Night
RTÉ
Learn French A1 with News | Slow Easy French for Beginners
LinguaWire
Bir bakışta
Anadolu Ajansı
Sky News Australia Update
Sky News Australia / NZ
120 jaar IJsfabriek Strombeek
The Podcast Planet
Chasing Scratch: A Golf Podcast
Chasing Scratch
コサキン ポッドキャストDEワァオ！
TBS RADIO
Unqualified Opinions
Stranded Panda
Todo
David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist
The cell and gene therapy industry faces massive hurdles—cost, scalability, and the need for highly skilled operators have historically limited the reach of these transformative treatments. advanced therapy medicinal pro...
What if the simple act of opening an incubator could undermine the consistency of your cell therapy manufacturing process? Unlike traditional biologics, the moment cells leave their incubator, subtle shifts in temperatur...
Digital transformation in biotech is no longer just about adopting new tools, it's about building a foundation where automation, data standardization, and AI integration actually lead to real value and long-term success....
Despite cutting-edge equipment and brilliant minds, biotech labs often find half their data trapped in difficult-to-access spreadsheets or isolated in silos, making true digital transformation a major, industry-wide hurd...
Host David Brühlmann returns for a focused solo episode to provide an honest, data-driven perspective on the evolving landscape of host selection for biologics manufacturing. Building on part one, David reviews five alte...
In this solo episode, David Brühlmann explores the evolving landscape of biologic manufacturing platforms beyond CHO (Chinese hamster ovary) cells. Drawing from previous interviews with platform pioneers and rigorous dat...
Funding novel therapeutics isn’t just “harder than ever”—the rules have changed entirely. The wild rush of capital into early-stage biotech during 2020–2021 gave way to a drought, making investor priorities sharper and s...
Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.Michael Rome, who leads therapeutics investing at Foresite Capital, brings a rare dual lens as both sci...
What happens between scientific discovery and clinical trials? For too many drug candidates, the answer is “failure”—not because the idea lacked merit, but because the critical handoff between discovery and IND-enabling ...
The gap between a “drug” and a true “product” is where many therapies fail.Milan Tomic, biotech veteran, GMP manufacturing expert, and founder of Albrem, has spent 30 years turning promising science into scalable, execut...
The "data lake" that was supposed to unify bioprocessing intelligence has, in most companies, become something else entirely: a data swamp, where information goes in and insight rarely comes back out. For anyone trying t...
When AI can draft a literature review in minutes, the question bioprocess educators can no longer avoid is this: what does a student actually need to learn?Steffen Kreye has a clear answer. As Professor of Industrial Bio...
Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?In Part 1, Yuta Lee, Founder and CEO of Accelerated Bio, walked through the biol...
What if the key to scalable, off-the-shelf cell therapy was hiding in tissue that surgeons discard every day?Yuta Lee, Founder and CEO of Accelerated Bio, has spent two decades building a cell therapy platform on exactly...
Are you still using one-factor-at-a-time experiments for biosimilar development, losing months, missing interactions, and risking costly dead-ends?In this episode, David Brühlmann, host of the Smart Biotech Scientist Pod...
Are you stuck screening endless compounds in biosimilar development and still not hitting your quality targets? Efficient compound screening is one of the toughest bottlenecks in biopharma, with outdated methods slowing ...
When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from process development into the broader consequences of that reality: the manufac...
The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the patient. Chantale Bernatchez has spent 20 years learning that lesson the ...
Getting an NDA signed shouldn't take weeks. If your CRO needs more than 48 hours to start the paperwork, your project timeline is already moving in the wrong direction.Ron Najafi knows what rigorous analytical work actua...
When drug safety fails, patients and entire markets pay the price. Understanding your CMC isn't just compliance — it's the line between therapeutic promise and product recall.Ron Najafi has lived that reality firsthand. ...
Completa el formulario de abajo. Asegúrate de seleccionar tanto País como Géneros.
Envíanos un mensaje abajo. Te responderemos en un plazo de 24 horas.